787 related articles for article (PubMed ID: 19891424)
1. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
2. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
Kellogg BA; Garrett L; Kovtun Y; Lai KC; Leece B; Miller M; Payne G; Steeves R; Whiteman KR; Widdison W; Xie H; Singh R; Chari RV; Lambert JM; Lutz RJ
Bioconjug Chem; 2011 Apr; 22(4):717-27. PubMed ID: 21425776
[TBL] [Abstract][Full Text] [Related]
3. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
Sun X; Widdison W; Mayo M; Wilhelm S; Leece B; Chari R; Singh R; Erickson H
Bioconjug Chem; 2011 Apr; 22(4):728-35. PubMed ID: 21391620
[TBL] [Abstract][Full Text] [Related]
4. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA
Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769
[TBL] [Abstract][Full Text] [Related]
5. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
Salomon PL; Singh R
Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
[TBL] [Abstract][Full Text] [Related]
6. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.
Kovtun YV; Audette CA; Ye Y; Xie H; Ruberti MF; Phinney SJ; Leece BA; Chittenden T; Blättler WA; Goldmacher VS
Cancer Res; 2006 Mar; 66(6):3214-21. PubMed ID: 16540673
[TBL] [Abstract][Full Text] [Related]
8. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.
Zhao RY; Wilhelm SD; Audette C; Jones G; Leece BA; Lazar AC; Goldmacher VS; Singh R; Kovtun Y; Widdison WC; Lambert JM; Chari RV
J Med Chem; 2011 May; 54(10):3606-23. PubMed ID: 21517041
[TBL] [Abstract][Full Text] [Related]
10. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.
Davis JA; Rock DA; Wienkers LC; Pearson JT
Drug Metab Dispos; 2012 Oct; 40(10):1927-34. PubMed ID: 22752008
[TBL] [Abstract][Full Text] [Related]
12. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
[TBL] [Abstract][Full Text] [Related]
13. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
[TBL] [Abstract][Full Text] [Related]
14. Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing.
Widdison WC; Ponte JF; Coccia JA; Lanieri L; Setiady Y; Dong L; Skaletskaya A; Hong EE; Wu R; Qiu Q; Singh R; Salomon P; Fishkin N; Harris L; Maloney EK; Kovtun Y; Veale K; Wilhelm SD; Audette CA; Costoplus JA; Chari RV
Bioconjug Chem; 2015 Nov; 26(11):2261-78. PubMed ID: 26355774
[TBL] [Abstract][Full Text] [Related]
15. Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates.
Goldmacher VS; Amphlett G; Wang L; Lazar AC
Mol Pharm; 2015 Jun; 12(6):1738-44. PubMed ID: 25635630
[TBL] [Abstract][Full Text] [Related]
16. Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies.
Widdison W; Wilhelm S; Veale K; Costoplus J; Jones G; Audette C; Leece B; Bartle L; Kovtun Y; Chari R
Mol Pharm; 2015 Jun; 12(6):1762-73. PubMed ID: 25826705
[TBL] [Abstract][Full Text] [Related]
17. Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes.
Fishkin N
Mol Pharm; 2015 Jun; 12(6):1745-51. PubMed ID: 25738231
[TBL] [Abstract][Full Text] [Related]
18. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
[TBL] [Abstract][Full Text] [Related]
19. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
[TBL] [Abstract][Full Text] [Related]
20. A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions.
Fishkin N; Maloney EK; Chari RV; Singh R
Chem Commun (Camb); 2011 Oct; 47(38):10752-4. PubMed ID: 21874179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
